

Resource Summary Report

Generated by RRID on Aug 3, 2026

PE anti-mouse CD80

RRID:AB_313128

Type: Antibody

Proper Citation

BioLegend Cat# 104707, RRID:AB_313128

Antibody Information

URL: http://antibodyregistry.org/AB_313128

Proper Citation: BioLegend Cat# 104707, RRID:AB_313128

Target Antigen: CD80

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD80

Description: This monoclonal targets CD80

Target Organism: mouse

Clone ID: Clone 16-10A1

Antibody ID: AB_313128

Vendor: BioLegend

Catalog Number: 104707

Alternative Catalog Numbers: 104708

Record Creation Time: 20250820T005429+0000

Record Last Update: 20250820T093103+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD80.

No alerts have been found for PE anti-mouse CD80.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen Y, et al. (2025) Neoadjuvant chemotherapy by liposomal doxorubicin boosts immune protection of tumor membrane antigens-based nanovaccine. *Cell reports. Medicine*, 6(1), 101877.

Xu C, et al. (2025) Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy. *Cell reports. Medicine*, 6(5), 102078.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. *Cell*.

Wang R, et al. (2025) An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α 2 shedding. *Cell reports. Medicine*, 6(3), 101981.

Song Z, et al. (2025) CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice. *Cancer immunology research*, 13(8), 1246.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. *Cell reports*, 44(10), 116314.

Amon L, et al. (2025) GM-CSF and specific type 2 cytokines induce CD103⁺ and CD301b⁺ cell states in cDC1s and cDC2s. *Cell reports*, 44(12), 116589.

Stegmann F, et al. (2024) *Legionella pneumophila* modulates macrophage functions through epigenetic reprogramming via the C-type lectin receptor Mincle. *iScience*, 27(9), 110700.

Basavaraja R, et al. (2024) PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies. *Cell reports. Medicine*, 5(7), 101649.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. *Cell reports*, 43(3), 113835.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. *Cell reports. Medicine*, 5(7), 101648.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8⁺ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Hori A, et al. (2024) MHC class I-dressing is mediated via phosphatidylserine recognition and is enhanced by polyI:C. *iScience*, 27(5), 109704.

Yeh AC, et al. (2024) Microbiota dictate T cell clonal selection to augment graft-versus-host disease after stem cell transplantation. *Immunity*, 57(7), 1648.

Sun Y, et al. (2023) Engineering irradiated tumor-derived microparticles as personalized vaccines to enhance anti-tumor immunity. *Cell reports. Medicine*, 4(12), 101303.

Li Y, et al. (2023) TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia. *iScience*, 26(8), 107451.

Zhao Y, et al. (2023) cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8⁺ T cell function and anti-tumor immunity. *Immunity*.

Lv F, et al. (2022) Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment. *iScience*, 25(1), 103639.

Vogel A, et al. (2022) JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. *Cell reports*, 38(8), 110420.